Plasminogen activator inhibitor-1 neointima of vein grafts: Its role in reduced fibrinolytic potential and graft failure

Circulation

Volumn 96, Issue 6, 1997, Pages 1783-1789

  Kauhanen, Petteri ^a   Sirén, Vappu ^b   Carpén, Olli ^b   Vaheri, Antti ^b   Lepäntalo, Mauri ^b   Lassila, Riitta ^a  

^a WIHURI RESEARCH INSTITUTE   (Finland)

^b NONE

Author keywords

Bypass; Fibrinolysis; Peripheral vascular disease; Plasminogen activator; Veins

Indexed keywords

PLASMINOGEN ACTIVATOR INHIBITOR;

ARTERY INTIMA PROLIFERATION; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORONARY ARTERY OBSTRUCTION; FIBRINOLYSIS; GRAFT FAILURE; HUMAN; HUMAN TISSUE; PRIORITY JOURNAL; VEIN GRAFT;

EID: 0030880770     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.96.6.1783     Document Type: Article

References (44)

1. Cox JL, Chiasson DA, Gotlieb AI. Stranger in a strange land: the pathogenesis of saphenous vein graft stenosis with emphasis on structural and functional differences between veins and arteries. Prog Cardiovasc Dis. 1991;34:45-68.
2. Ip JH, Fuster V, Badimon L, Badimon J, Taubman MB, Chesebro JH. Syndromes of accelerated atherosclerosis: role of vascular injury and smooth muscle cell proliferation. J Am Coll Cardiol. 1990;15:1667-1687.
3. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature. 1993;362:801-809.
4. Jackson CL, Raines EW, Ross R, Reidy MA. Role of endogenous platelet-derived growth factor in arterial smooth muscle cell migration after balloon catheter injury. Arterioscler Thromb. 1993; 13:1218-1226.
5. Clowes AW, Clowes MM, Au YPT, Reidy MA, Belin D. Smooth muscle cells express urokinase during mitogenesis and tissue-type plasminogen activator during migration in injured rat carotid artery. Circ Res. 1990;67:61-67.
6. Yao JST, Bergan JJ, Kwaan HC. Quantitation of fibrinolytic activity in venous and prosthetic arterial grafts. Arch Surg. 1974;109: 163-167.
7. Risberg B. Fibrinolysis in grafted arteries and veins. Thromb Haemost. 1978;40:512-517.
8. Wiman B. Plasminogen activator inhibitor 1 (PAI-1) in plasma: its role in thrombotic disease. Thromb Haemost. 1995;74:71-76.
9. Juhan-Vague I, Valadier J, Alessi MC, Aillaud MF, Ansaldi J, Philip-Joet C, Holvoet P, Serradimigni A, Collen D. Deficient t-PA release and elevated PA inhibitor levels in patients with spontaneous or recurrent deep venous thrombosis. Thromb Haemost. 1987;57:67-72.
10. Earnshaw JJ, Westby JC, Makin GS, Hopkinson BR. Defective fibrinolysis: a risk factor in early femoropopliteal graft thrombosis. Br J Surg. 1987;74:932-935.
11. Moor E, Hamsten A, Blombäck M, Herzfeld I, Wiman B, Ryden L. Haemostatic factors and inhibitors and coronary artery bypass grafting: preoperative alterations and relations to graft occlusion. Thromb Haemost. 1994;72:335-342.
12. Larsson Å, Åstedt B. Immunohistochemical localisation of tissue plasminogen activator and urokinase in the vessel wall. J Clin Pathol. 1985;38:140-145.
13. Lupu F, Heim A, Bachmann F, Hurni M, Kakkar VV, Kruithof EKO. Plasminogen activator expressions in human atherosclerotic lesions. Arterioscler Thromb Vasc Biol. 1995;15:1444-1455.
14. Ragnunath PN, Tomaszewski JE, Brady ST, Caron RJ, Okada SS, Barnathan ES. Plasminogen activator system in human coronary atherosclerosis. Arterioscler Thromb Vasc Biol. 1995;15:1432-1443.
15. Zwolak RM, Adams MC, Clowes AW. Kinetics of vein graft hyperplasia: association with tangential stress. J Vasc Surg. 1987;5. 126-136.
16. Kohler TR, Kirkman T, Clowes AW. Effect of heparin on adaption of vein grafts to arterial circulation. Arteriosclerosis. 1989;9:523-528.
17. Mann MJ, Gibbons GH, Kernoff RS, Diet FP, Tsao PS, Cooke JP, Kaneda Y, Dzau VJ. Genetic engineering of vein grafts resistant to atherosclerosis. Proc Nail Acad Sci USA. 1995;92:4502-4506.
18. Brody JI, Pickering NJ, Fink GB. Abnormalities of thrombo-modulin and tissue plasminogen activator in occluded aortocoronary grafts detected by immunohistochemistry. Trans Assoc Am Physicians. 1988;101:79-87.
19. Gallichio M, Argyriou S, Ianches G, Filonzi EL, Zoellner H, Hamilton JA, McGrath K, Wojta J. Stimulation of PAI-1 expression in endothelial cells by cultured vascular smooth muscle cells. Arterioscler Thromb. 1994;14:815-823.
20. Amman V, Nilsson A, Stemme S, Risberg B, Rymo L. Expression of plasminogen activator inhibitor-1 mRNA in healthy, atherosclerotic and thrombotic human arteries and veins. Thromb Res. 1994;76:487-499.
21. Schneiderman J, Sawdey MS, Keeton MR, Bordin GM, Bernstein EF, Dilley RB, Loskutoff DJ. Increased type 1 plasminogen activator inhibitor gene expression in atherosclerotic human arteries. Proc Natl Acad Sci USA. 1992;89:6998-7002.
22. Lupu F, Bergonzelli GE, Heim DA, Cousin E, Genton CY, Bachmann F, Kruithof EKO. Localization and production of plasminogen activator inhibitor-1 in human healthy and atherosclerotic arteries. Arterioscler Thromb. 1993;13:1090-1100.
23. Padró T, Emeis JJ, Steins M, Schmid KW, Kienast J. Quantification of plasminogen activators and their inhibitors in the aortic vessel wall in relation to the presence and severity of atherosclerotic disease. Arterioscler Thromb. 1995;15:893-902.
24. Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature. 1970;227:680-685.
25. Granelli-Piperno A, Reich E. A study of protease and protease-inhibitor complexes in biological fluids. J Exp Med. 1978;146:223-234.
26. Booth NA. The laboratory investigation of the fibrinolytic system. In: Thompson JM, ed. Blood Coagulation and Haemostasis: A Practical Guide. 4th ed. Edinburgh, Scotland: Churchill Livingstone; 1991:136-138.
27. Stephens RW, Leung K-C, Pöllänen J, Salonen E-M, Vaheri A. Microplate immunocapture assay for plasminogen activators and their specific inhibitors. J Immunol Methods. 1987;105:245-251.
28. Verde P, Stoppelli MP, Galeffi P, Di Nocera P, Blasi F. Identification and primary sequence of an unspliced human urokinase poly (A)+ RNA. Proc Natl Acad Sci U S A. 1984;81:4727-4731.
29. Andreasen PA, Riccio A, Welinder KG, Douglas R, Sartorio R, Nielsen LS, Oppenheimer C, Blasi F, Danø K. Plasminogen activator inhibitor type-1: reactive center and aminoterminal heterogeneity determined by protein and cDNA sequencing. FEBS Lett. 1986;209:213-218.
30. Ginsburg D, Zeheb R, Yang AY, Rafferty UM, Andreasen PA, Nielsen L, Danø K, Lebo RV, Gelehrter TD. cDNA cloning of human piasminogen activator-inhibitor from endothelial cells. J Clin Invest. 1986;78:1673-1680.
31. Diamond SL, Eskin SG, McIntire LV. Fluid flow stimulates tissue plasminogen activator secretion by cultured human endothelial cells. Science. 1989;243:1483-1485.
32. Tipping PG, Davenport P, Gallichio M, Apostopoulos J, Wojta J. Atheromatous plaque macrophages produce plasminogen activator inhibitor type-1 and stimulate its production by endothelial cells and vascular smooth muscle cells. Am J Pathol. 1993;143:875-885.
33. Peltonen S, Lassila R, Lepäntalo M. Increased circulating plasminogen activator inhibitor-1 in patients with patent femorodistal venous bypass. Thromb Res. 1996;82:369-377.
34. Carmeliet PFM. Physiological consequences of over- or underexpression of fibrinolytic system components in transgenic mice. Baillieres Clin Haematol. 1995;8:391-402.
35. Schneiderman J, Bordin GM, Engelberg I, Adar R, Seiffert D, Thinnes T, Bernstein EF, Dilley RB, Loskutoff DJ. Expression of fibrinolytic genes in atherosclerotic abdominal aortic aneurysm wall. J Clin Invest. 1995;96:639-645.
36. Robbie LA, Booth NA, Brown PAJ, Bennet B. Inhibitors of fibrinolysis are elevated in atherosclerotic plaque. Arterioscler Thromb Vasc Biol. 1996;16:539-545.
37. Carmeliet P, Collen D. Role of the plasminogen/plasmin system in thrombosis, hemostasis, restenosis and atherosclerosis. Trends Cardiovasc Med. 1995;5:117-122.
38. Labarrere CA, Pitts D, Nelson DR, Faulk WP. Vascular tissue piasminogen activator and the development of coronary artery disease in heart-transplant recipients. N Engl J Med. 1995;333: 1111-1116.
39. Hoch JR, Stark VK, Turnipseed WD. The temporal relationship between the development of vein graft intimai hyperplasia and growth factor gene expression. J Vasc Surg. 1995;22:51-58.
40. Davies MG, Hagen P-O. Pathophysiology of vein graft failure: a review. Eur J Vasc Endovasc Surg. 1995;9:7-18.
41. Sisto T, Ylä-Herttuala S, Luoma J, Riekkinen H, Nikkari T. Biochemical composition of human internal mammary artery and saphenous vein. J Vasc Surg. 1990;11:418-422.
42. Predel H-G, Yang Z, von Segesser L, Turina M, Bühler FR, Lüscher TL. Implications of pulsatile stretch on growth of saphenous vein and mammary artery smooth muscle. Lancet. 1992; 340:878-879.
43. Lüscher TF, Diederich D, Siebenmann R, Lehmannn K, Stultz P, von Segesser L, Yang Z, Turina M, Grädel E, Weber E, Bühler RF. Difference between endothelium-dependent relaxation in arterial and in venous coronary bypass grafts. N Engl J Med. 1988;319: 462-467.
44. Yang Z, Stulz P, von Segesser L, Bauer E, Turina M, Lüscher TF. Different interactions of platelets with arterial and venous coronary bypass vessels. Lancet. 1991;337:939-943.